Search Results

pharmacological effects in the treatment of several neurological disorders including, epilepsy, Parkinson’s disease , and Alzheimer’s disease.

knockdown regulates the expression and alternative splicing of genes associated with aphasia-related diseases ochraceus quorum sensing through the GprC-AcyA pathway Deciphering the genetic landscape of lumpy skin disease

Although blockade of GPR84 may potentially prove effective also in diseases associated with inflammation

study in Q1 2023 and continue to evaluate the path forward for dipraglurant in a number of interesting disease

cellulose-degrading enzymes Functional Water Channels Within the TSH Receptor - a new paradigm for TSH action with disease launch LAB eN², a translational drug discovery accelerator, to address innovation gap in cardiometabolic diseases

with the fact that dysregulation of compartmentalized GPCR signaling has been implicated in various diseases aberrant endosomal signaling by GPCRs has been linked to disorders such as cancer, neurodegenerative diseases Insights into Nuclear G-Protein-Coupled Receptors as Therapeutic Targets in Non-Communicable Diseases

protein-coupled receptor (GPCR) kinases (GRKs) are associated with the pathophysiology of Alzheimer's disease

focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases

GPCRs in Cardiology, Endocrinology, and Taste Gender Differences in GRK2 in Cardiovascular Diseases and Manager Director of Molecular Pharmacology, Discovery Biology Staff Scientist/Senior Staff Scientist, Disease

determines the potential of a GPCR for arrestin-biased agonism The roles of RGS proteins in cardiometabolic disease Receptor Responses to Sequential Injections of Pure and Mixed Sweeteners GPCRs involved in metabolic diseases

Portal Venous Blood as a Possible Mechanism for Microbiota Effects on the Immune System, and Western Diseases concept to metabolomics: New insights into pregnenolone function Molecular characterization of lumpy skin disease

plant-like” behavior in important human cell regulator, opening up a new drug target for cancer, other diseases Neuroscience Diverse signaling mechanisms and heterogeneity of astrocyte reactivity in Alzheimer's disease

protein-coupled A2A adenosine receptor (A2AAR) have been considered promising agents to treat Parkinson's disease

Neisseria meningitidis is a Gram-negative opportunistic pathogen that is responsible for causing human diseases

disaccharide sugar with known pro‐autophagy activity and effective in alleviating diverse inflammatory diseases

Modulation of GPCR receptors common to gut inflammatory diseases and neuronal disorders, Alzheimer's and Parkinson's diseases as druggable targets through Withania somnifera bioactives: an in silico study

numerous GPCRs have been studied for their impact on pathologic conditions, including cardiovascular diseases

macrophages and monocytes, and play a critical role in neuroinflammatory conditions such as Alzheimer's disease

including expensive cost of reagents, optimizing sensor expression levels and adapting these systems to disease-relevant the development of the BERKY and the ONE-GO biosensors, designed to facilitate their application in disease

Founder & CEO, and Zach Jonasson, CFO & CBO at Absci Octant: A Next Generation Approach to Genetic Disease allosteric communication networks GPTrans: A Biological Language Model-Based Approach for Predicting Disease-Associated

/3 APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease transport by CCHCR1 via direct interaction Industry News Novartis Lutathera® significantly reduced risk of disease

clients worldwide in identifying and optimizing new therapeutic opportunities across a wide range of disease

conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs (G protein-coupled receptors) in disease-relevant

intracellular protein complexes and solute carriers, are relevant to immunology indications and rare diseases

Several S1PR therapeutic drugs have been developed to treat these diseases; however, they lack receptor

free fatty acid receptors (FFARs), now regarded as targets for therapeutic intervention for metabolic diseases such as liver disease, obesity and diabetes (Secor et al. 2021; Wold and Zhou 2018).

effects of CB2 receptor activation, make this receptor an intriguing target for treating schizophrenia, a disease

understanding the modulatory role of the membrane environment on the organization and dynamics of GPCRs in diseases

(GPCR) targets with a goal of creating new drug discovery programs in the area of gastrointestinal diseases

Molecular Endocrinology and Pharmacology Laboratory team who are investigating new ways to tackle the disease-inducing